Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04973007 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

StatusTerminated
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results posted: Sep 25, 2026 Primary endpoints: 5 to 4 · Secondary endpoints: details revised at 5 of 5 entries · Eligibility criteria expanded, about 5 words · 1 more Show 4 more changesShow less
    • Primary endpoints: 5 to 4
    • Secondary endpoints: details revised at 5 of 5 entries
    • Eligibility criteria expanded, about 5 words
    • Study description expanded, about 3 words
  2. Secondary endpoints: details revised at 4 of 5 entriesv11
  3. Primary endpoints: 3 to 5 Secondary endpoints: 4 to 5v10 Show 1 more changeShow less
    • Secondary endpoints: 4 to 5

    See this version in full on ClinicalTrials.gov ↗

  4. Sponsor's reason: Low accrual to Low Accrual Study title expanded, about 2 wordsv9 Show 1 more changeShow less
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Terminated Sponsor's reason: Low accrual Enrollment target: estimated 55 to confirmed 10 · Primary completion date changed from estimate of Dec 31, 2025 to May 6, 2025 · Study completion date changed from estimate of Dec 9, 2026 to May 8, 2025 · 1 morev8 Show 4 more changesShow less
    • Enrollment target: estimated 55 to confirmed 10
    • Primary completion date changed from estimate of Dec 31, 2025 to May 6, 2025
    • Study completion date changed from estimate of Dec 9, 2026 to May 8, 2025
    • Site details revised
Show 6 earlier versionsHide 6 earlier versions
  1. Site contact updatedv7
  2. Primary completion date: Aug 9, 2024 to Dec 31, 2025 Completion date: Dec 9, 2024 to Dec 9, 2026v6 Show 1 more changeShow less
    • Completion date: Dec 9, 2024 to Dec 9, 2026
  3. Primary completion date: Aug 9, 2023 to Aug 9, 2024 Completion date: Dec 9, 2023 to Dec 9, 2024v5 Show 1 more changeShow less
    • Completion date: Dec 9, 2023 to Dec 9, 2024
  4. Re-verified, no change to tracked fieldsv4
  5. Primary completion date: Aug 9, 2021 to Aug 9, 2023 Completion date: Aug 9, 2022 to Dec 9, 2023v3 Show 1 more changeShow less
    • Completion date: Aug 9, 2022 to Dec 9, 2023
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 15, 2021 to Jun 22, 2021 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 15, 2021 to Jun 22, 2021
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
Trial Details
NCT Number NCT04973007
Lead Sponsor University of Colorado, Denver
Collaborators: Bracco Diagnostics, Inc, National Cancer Institute (NCI)
Conditions Oligometastatic Disease, Liver Metastases, Colorectal Cancer
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov